Andrew C. Novick

American Urological Association, Cleveland Clinic

Papers

Total Citations

1,915

H-Index

About

Andrew C. Novick is a pioneering urologic oncologist whose research has fundamentally shaped the management of kidney cancer. His primary contributions lie in nephron-sparing surgery and the development of minimally invasive ablation technologies for renal masses. Novick’s landmark work includes chairing the 2009 American Urological Association "Guideline for Management of the Clinical T1 Renal Mass," a seminal paper with over 1,800 citations that established evidence-based standards for treating small kidney tumors, emphasizing partial nephrectomy over radical nephrectomy whenever possible. This guideline has become a cornerstone of urologic oncology, directly influencing surgical practice worldwide. Additionally, Novick conducted early investigations into novel ablation techniques, such as the "Initial evaluation of cyberknife technology for extracorporeal renal tissue ablation" (76 citations), demonstrating the potential of stereotactic radiosurgery for non-invasive kidney tumor treatment. His research has significantly advanced patient outcomes by preserving renal function and reducing treatment morbidity. A former Chairman of the Glickman Urological & Kidney Institute at the Cleveland Clinic, Novick’s work continues to guide clinical decision-making for the hundreds of thousands of patients diagnosed with renal masses annually.